Arbutus Biopharma Corp
NASDAQ:ABUS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
US |
|
L
|
Lotus Ventures Inc
CNSX:J
|
CA |
|
R
|
Resolute Holdings Management Inc
NASDAQ:RHLD
|
US |
|
ESR-REIT
OTC:CGIUF
|
SG |
|
E
|
Essen Tech Co Ltd
KOSDAQ:043340
|
KR |
|
C
|
Caster Co Ltd
TSE:9331
|
JP |
|
B
|
Blende Silver Corp
XTSX:BAG
|
CA |
|
Apollo Minerals Ltd
ASX:AON
|
AU |
|
Neojapan Inc
TSE:3921
|
JP |
|
N
|
Namwiwat Medical Corp PCL
SET:NAM
|
TH |
|
Magillem Design Services SA
PAR:MLMGL
|
FR |
|
I
|
Ikonisys SA
F:9W8
|
FR |
Wall St Price Targets
ABUS Price Targets Summary
Arbutus Biopharma Corp
According to Wall Street analysts, the average 1-year price target for
ABUS is 5.61 USD with a low forecast of 5.56 USD and a high forecast of 5.78 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is ABUS's stock price target?
Price Target
5.61
USD
According to Wall Street analysts, the average 1-year price target for
ABUS is 5.61 USD with a low forecast of 5.56 USD and a high forecast of 5.78 USD.
What is the Revenue forecast for Arbutus Biopharma Corp?
Projected CAGR
-46%
Over the last 13 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 2 years is -46%.